Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Emerging roles of ADAM6 and PRSS1 as novel diagnostic/prognostic biomarkers for acute lymphoblastic and myeloid leukemia in adults

Fig. 2

Serum levels of PRSS1 in acute leukemia patients. A PRSS1 levels in acute leukemia patients (n = 76) compared to healthy control subjects (n = 55). B PRSS1 levels in ALL patients (n = 36) and AML patients (n = 40) compared to healthy control subjects (n = 55). Box plots represent the interquartile range, the line inside the box represents the median, and the bars represent the minimum and maximum values. Shown p-Values are for Kruskal–Wallis test. ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; and PRSS1, Serine protease 1

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us